Wellbutrin Titration Down
When discontinuing Wellbutrin XL 300 mg, taper by reducing to 150 mg once daily for at least one week before complete discontinuation. This is the explicit FDA-approved tapering schedule 1.
FDA-Approved Tapering Protocol
The FDA drug label provides clear guidance: for patients on Wellbutrin XL 300 mg daily, decrease the dose to 150 mg once daily prior to discontinuation 1. This represents a 50% dose reduction maintained for a minimum period before stopping completely.
For seasonal affective disorder specifically, the label recommends a 2-week taper beginning in early spring (fourth week of March), which involves reducing from 300 mg to 150 mg before complete cessation 1.
Why This Matters for Patient Outcomes
Abrupt discontinuation of bupropion can cause withdrawal symptoms including irritability, anxiety, insomnia, headache, and generalized body aches 2. While bupropion withdrawal is generally considered less severe than with SSRIs, it is real and can significantly impact quality of life during the discontinuation period.
Key Clinical Considerations
Avoid alternate-day dosing strategies. Recent pharmacokinetic modeling demonstrates that dosing antidepressants every other day causes pronounced fluctuations in receptor occupancy, substantially increasing withdrawal symptom risk 3. This applies across antidepressant classes and cannot be recommended as a safe tapering strategy.
Patient-Specific Factors That May Require Slower Tapering:
- Duration of treatment: Patients on bupropion for >6 months may need more gradual tapers
- Prior withdrawal experiences: History of withdrawal symptoms with any antidepressant warrants extra caution
- Higher doses: Patients on 450 mg daily should taper to 300 mg, then 150 mg, with each step lasting 1-2 weeks minimum
- Concurrent psychiatric conditions: Monitor more closely for symptom re-emergence
Monitoring During Taper:
Follow patients every 2-4 weeks during the tapering process 4. The first dose reduction is critical—if withdrawal symptoms emerge, pause the taper or slow the pace. Distinguish withdrawal symptoms (onset within days, improve with dose restoration) from depression relapse (gradual onset over weeks, doesn't improve with dose restoration).
Common Pitfalls to Avoid
Don't confuse withdrawal with relapse: Withdrawal symptoms typically begin within 1-5 days of dose reduction and include physical symptoms (headache, body aches) alongside mood changes. Depression relapse develops more gradually over weeks.
Don't rush patients who struggle: While many patients tolerate the standard taper well 5, approximately 50% experience some withdrawal symptoms 4. For those who struggle, extend the 150 mg phase to several weeks or even months.
Don't use alternate-day dosing: This creates unnecessary receptor occupancy fluctuations and increases withdrawal risk 3.
Special Populations
Hepatic impairment (Child-Pugh 7-15): Maximum dose is 150 mg every other day, so discontinuation from this dose can be more abrupt, but monitor closely 1.
Renal impairment (GFR <90): Consider extending the taper duration given altered pharmacokinetics 1.
The evidence strongly supports a structured, gradual approach rather than abrupt cessation, with the FDA-recommended minimum being a reduction to 150 mg for at least one week before complete discontinuation 1.